Jul. 11 at 1:13 PM
$TSHA ..BoA gave us an
$8.00 target today(July 11/25) as
$ACAD Dayblue is their reference...nice!...We have Kristen over at CantorFitz....with a
$13...great!...This FDA, while still "new" on the job....can not be ruled out for throwing a wrench or two towards investors...risk/reward is always on the table. Quick peek over at DMD player
$CAPR this morning...only invest what you can afford to lose...going to listen to their 'explanation' for that drop...just some thoughts. Good trading and glta
"Jun 11, 2025, 11:25 AM
Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on Taysha Gene Therapies (TSHA) to
$13 from
$7 and keeps an Overweight rating on the shares. After having attended the IRSF Rett Syndrome Scientific Meeting and spent additional time with Taysha mgmt, the firm has “very high conviction” that the TSHA-102 pivotal trial will succeed...Following data and regulatory path updates, the firm is increasing its view of the odds of success for TSHA-102 to 70% "
